Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07994525 in Relapsed/Refractory Multiple Myeloma
NCT07426757Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Jul 2026
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of PF-07994525 in multiple myeloma (MM) (2 arms), sponsored by Pfizer. Primary endpoints: Adverse Events and Dose-limiting Toxicities. Started Jul 2026; status: recruiting.
02
Drugs
PF-07994525
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07426757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07426757.